Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis

Mier-García, Juan F.; Ospina-Santa, Stefanía; Orozco-Mera, Javier; Ma, Ruichong; Plaha, Puneet

doi:10.1007/s11060-023-04409-0

Cited by 10 publications

(4 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Post mortembased studies also indicate that brain tumors account for ~2-5% of all cancers, an incidence that approximates that seen in humans [1]. Clinical management of brain tumors in pet dogs also closely parallels approaches used in humans, with surgery, radiotherapy, and chemotherapy remaining important therapeutic modalities, which can improve the quality and quantity of life in patients with a variety of brain tumors [1,4,5]. However, as also occurs in humans, despite multimodality treatments, tumor recurrence and therapeutic resistance remain major modes of treatment failure and sources of morbidity and death, particularly with malignant brain tumors [4,5].…”

Section: Introductionmentioning

confidence: 93%

“…Clinical management of brain tumors in pet dogs also closely parallels approaches used in humans, with surgery, radiotherapy, and chemotherapy remaining important therapeutic modalities, which can improve the quality and quantity of life in patients with a variety of brain tumors [1,4,5]. However, as also occurs in humans, despite multimodality treatments, tumor recurrence and therapeutic resistance remain major modes of treatment failure and sources of morbidity and death, particularly with malignant brain tumors [4,5]. Thus, there are currently unmet clinical needs to develop and evaluate novel treatments that can further improve outcomes in humans and dogs with brain tumors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Phase I/II Trial of Urokinase Plasminogen Activator-Targeted Oncolytic Newcastle Disease Virus for Canine Intracranial Tumors

Rossmeisl,

King,

Robertson

et al. 2024

Cancers

View full text Add to dashboard Cite

Neurotropic oncolytic viruses are appealing agents to treat brain tumors as they penetrate the blood–brain barrier and induce preferential cytolysis of neoplastic cells. The pathobiological similarities between human and canine brain tumors make immunocompetent dogs with naturally occurring tumors attractive models for the study of oncolytic virotherapies. In this dose-escalation/expansion study, an engineered Lasota NDV strain targeting the urokinase plasminogen activator system (rLAS-uPA) was administered by repetitive intravenous infusions to 20 dogs with intracranial tumors with the objectives of characterizing toxicities, immunologic responses, and neuroradiological anti-tumor effects of the virus for up to 6 months following treatment. Dose-limiting toxicities manifested as fever, hematologic, and neurological adverse events, and the maximum tolerated dose (MTD) of rLAS-uPA was 2 × 107 pfu/mL. Mild adverse events, including transient infusion reactions, diarrhea, and fever were observed in 16/18 of dogs treated at or below MTD. No infectious virus was recoverable from body fluids. Neutralizing antibodies to rLAS-uPA were present in all dogs by 2 weeks post-treatment, and viral genetic material was detected in post-treatment tumors from six dogs. Tumor volumetric reductions occurred in 2/11 dogs receiving the MTD. Systemically administered rLAS-uPA NDV was safe and induced anti-tumor effects in canine brain tumors, although modifications to evade host anti-viral immunity are needed to optimize this novel therapy.

show abstract

Section: Introductionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Phase I/II Trial of Urokinase Plasminogen Activator-Targeted Oncolytic Newcastle Disease Virus for Canine Intracranial Tumors

Rossmeisl,

King,

Robertson

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…In addition, supra-total resection, i.e. resecting beyond the tumor bulk mass and into brain, results in improved survival [6], [7]. However, resecting healthy brain is not an ideal approach as it can result in functional deficits and morbidity [8].…”

Section: Introductionmentioning

confidence: 99%

Finite element analysis of a neural implant for cytostatic hypothermia and a novel heat management system

Enam,

Chen,

Bellamkonda

2024

Preprint

View full text Add to dashboard Cite

The treatment of glioblastoma (GBM) presents significant challenges, with median survival rates remaining low despite standard-of-care therapies. This study expands upon the findings of a novel approach to managing GBM, namely cytostatic hypothermia, through the computational evaluation of a fully implantable system. Our proposed system utilizes a multi-probe array and a novel artificial internal circulation system (AICS) to achieve homogeneous cooling within the brain without overheating any portion of the body. Finite-element modeling was employed to simulate bioheat transfer and fluid dynamics. Our results indicate that the multi-probe array can attain local tissue temperatures within the cytostatic range (20 to 28degC) while minimizing thermal gradients. The use of multiple narrow, thermally conductive probes enhances cooling uniformity with minimal tissue displacement. The revolutionary AICS provides a form of heat management that has not previously been attempted to the best of our knowledge. In this study, it successfully facilitates the transfer of heat from the intracranial region to the skin in the body. Future work will focus on device prototyping and validation through in vitro and in vivo studies in large animal models. These simulations suggest that the proposed intracranial cooling system makes cytostatic hypothermia a practicable approach against GBM. Furthermore, this approach to internal heat management may also open new avenues for treating neurological conditions through local and chronic hypothermia, extending beyond the short-duration (acute) cooling methods currently tested.

show abstract

“…Gross total surgical resection (GTR) or maximal safe resection followed by radiochemotherapy is considered the treatment of choice for newly diagnosed glioblastoma [3][4][5]. The extent of resection has been extensively associated with prolonged survival in these tumors [6,7].…”

Section: Introductionmentioning

confidence: 99%

Current Knowledge about the Peritumoral Microenvironment in Glioblastoma

Trevisi,

Mangiola

2023

Cancers

View full text Add to dashboard Cite

Glioblastoma is a deadly disease, with a mean overall survival of less than 2 years from diagnosis. Recurrence after gross total surgical resection and adjuvant chemo-radiotherapy almost invariably occurs within the so-called peritumoral brain zone (PBZ). The aim of this narrative review is to summarize the most relevant findings about the biological characteristics of the PBZ currently available in the medical literature. The PBZ presents several peculiar biological characteristics. The cellular landscape of this area is different from that of healthy brain tissue and is characterized by a mixture of cell types, including tumor cells (seen in about 30% of cases), angiogenesis-related endothelial cells, reactive astrocytes, glioma-associated microglia/macrophages (GAMs) with anti-inflammatory polarization, tumor-infiltrating lymphocytes (TILs) with an “exhausted” phenotype, and glioma-associated stromal cells (GASCs). From a genomic and transcriptomic point of view, compared with the tumor core and healthy brain tissue, the PBZ presents a “half-way” pattern with upregulation of genes related to angiogenesis, the extracellular matrix, and cellular senescence and with stemness features and downregulation in tumor suppressor genes. This review illustrates that the PBZ is a transition zone with a pre-malignant microenvironment that constitutes the base for GBM progression/recurrence. Understanding of the PBZ could be relevant to developing more effective treatments to prevent GBM development and recurrence.

show abstract

Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis

Cited by 10 publications

References 61 publications

Phase I/II Trial of Urokinase Plasminogen Activator-Targeted Oncolytic Newcastle Disease Virus for Canine Intracranial Tumors

Phase I/II Trial of Urokinase Plasminogen Activator-Targeted Oncolytic Newcastle Disease Virus for Canine Intracranial Tumors

Finite element analysis of a neural implant for cytostatic hypothermia and a novel heat management system

Current Knowledge about the Peritumoral Microenvironment in Glioblastoma

Contact Info

Product

Resources

About